Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer

Summary

This randomized phase II trial studies how well radiation therapy and pembrolizumab work in treating patients with urothelial bladder cancer that is restricted to the site of origin, without evidence of spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving radiation therapy and pembrolizumab may work better in treating urothelial bladder cancer.

Timeline

Start

2018-07-18

Primary completion

2020-12-31

Completion

2022-12-31

Outcome

Outcome not reported

Stopped (Enrollment): “Study withdrawn prior to patient enrollment”

Drugs

Indications